文献速递细菌感染、耐药与抗菌药物

葡萄球菌盒式染色体mec扩增作为临床耐甲氧西林金黄色葡萄球菌对头孢比罗耐药机制

Staphylococcal cassette chromosome mec amplification as a mechanism for ceftobiprole resistance in clinical methicillin-resistant Staphylococcus aureus isolates.
PubMed 文献 · Clin Microbiol Infect · 2022-04-01

研究检测472株耐甲氧西林金黄色葡萄球菌(MRSA)对头孢比罗(BPR)的敏感性,发现471株敏感(MIC 0.25–2 mg/L),1株耐药;耐药株携带两份SCCmec重复序列,且体外BPR暴露可诱导ST239 MRSA发生SCCmec扩增并出现mecA等基因突变。

要点

  • 471/472株MRSA对BPR敏感,MIC范围0.25–2 mg/L。
  • CA-MRSA较HA-MRSA更敏感(MIC50 0.5 vs 2 mg/L,p<0.001)。
  • SCCmec IV/V型较II/III型更敏感(MIC50 1/0.5 vs 2 mg/L,p<0.001)。

核心结论

  • BPR对中国MRSA分离株显示显著抗菌活性,但上市前已出现耐药株值得关注。
  • 多个基因和通路可能参与MRSA对BPR耐药的发生,纳米孔测序可揭示串联重复介导的耐药机制。

研究设计与样本

  • 研究评估472株MRSA分离株对BPR的敏感性,用琼脂稀释法测定MIC。
  • 对BPR耐药株进行Illumina短读长和MinION长读长测序。
  • 选取ST5、ST59和ST239 MRSA分离株,暴露于递增浓度BPR,对产生的耐药突变株测序。

主要发现

  • 471株MRSA对BPR敏感,MIC范围0.25–2 mg/L。
  • CA-MRSA(MIC50=0.5 mg/L;MIC90=2 mg/L)较HA-MRSA(MIC50=2 mg/L;MIC90=2 mg/L)更敏感(p<0.001)。
  • SCCmec IV型(MIC50=1 mg/L;MIC90=1 mg/L)或V型(MIC50=0.5 mg/L;MIC90=1 mg/L)较II或III型(MIC50=2 mg/L;MIC90=2 mg/L)更敏感(p<0.001)。
  • 纳米孔测序显示BPR耐药MRSA分离株携带两份SCCmec重复序列。
  • BPR暴露可诱导ST239 MRSA分离株SCCmec扩增,其他谱系未观察到扩增;诱导的耐药株获得mecA及guaA、guaB、relA、rpoA、oatA等基因突变,推测为BPR耐药发展的 contributory 因素。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: In this study, we evaluated the ceftobiprole (BPR) susceptibilities of 472 methicillin-resistant Staphylococcus aureus (MRSA) isolates, and investigated the mechanisms underlying BPR resistance. METHODS: For all MRSA isolates, BPR MIC was determined by agar dilution. We sequenced the BPR-resistant isolates through Illumina short- and MinION long-read sequencing. We also selected MRSA isolates of ST5, ST59, and ST239, and exposed them to increasing BRP concentrations. The isolated mutants developing BPR resistance were sequenced. RESULTS: A total of 471 MRSA isolates were susceptible to BPR, with MICs ranging from 0.25 to 2 mg/L. Compared with HA-MRSA isolates (MIC50 = 2 mg/L; MIC90 = 2 mg/L), CA-MRSA isolates (MIC50 = 0.5; MIC90 = 2 mg/L) were more susceptible to BPR (p < 0.001). Compared with isolates with staphylococcal cassette chromosome mec (SCCmec) type II or III (MIC50 = 2 mg/L; MIC90 = 2 mg/L), isolates with SCCmec type IV (MIC50 = 1 mg/L; MIC90 = 1 mg/L) or V (MIC50 = 0.5 mg/L; MIC90 = 1 mg/L) were more susceptible to BPR (p < 0.001). Nanopore sequencing revealed two copies of SCCmec repeats in the BPR-resistant MRSA isolate. In addition, SCCmec amplification could be induced by BPR exposure in ST239 MRSA isolates; however, no amplification was observed in the other lineages. The induced BPR-resistant MRSA isolates also acquired mutations in mecA and other genes, such as guaA, guaB, relA, rpoA, and oatA, which were speculated as factors contributing to BPR-resistance development. DISCUSSION: BPR showed significant antibacterial activity against MRSA isolates in China; however, the emergence of a BPR-resistant isolate before its launch was a cause for concern. Multiple genes and pathways are potentially involved in the development of BPR resistance in MRSA, and our data demonstrated the role of nanopore-sequencing in revealing the tandem repeat-mediated resistance mechanism in MRSA.

来源:Clin Microbiol Infect,查看原文。版权归原作者所有。

引用

  1. Zhu F, Zhuang H, Di L, et al. Staphylococcal cassette chromosome mec amplification as a mechanism for ceftobiprole resistance in clinical methicillin-resistant Staphylococcus aureus isolates. Clin Microbiol Infect. 2022. PMID: 35378270. doi:10.1016/j.cmi.2022.03.009

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。